首页> 外文期刊>The Journal of Urology >Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
【24h】

Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.

机译:盐酸奥昔布宁局部用凝胶治疗膀胱过度活动症的疗效和安全性:一项随机,双盲,安慰剂对照的多中心研究。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: We assessed the efficacy and safety of oxybutynin chloride topical gel vs placebo in adults with overactive bladder. MATERIALS AND METHODS: Men and women 18 years or older with urge predominant urinary incontinence were enrolled in randomized, parallel group, double-blind, placebo controlled Study OG05009 done at 76 clinics in the United States. Eligible patients were assigned to receive 1 gm oxybutynin chloride topical gel (10% weight per weight ethanol based formulation of oxybutynin) or matching placebo once daily for 12 weeks. Efficacy was assessed using data from 3-day urinary diaries and the primary outcome was the change from baseline in the number of urge incontinence episodes. Safety was monitored through adverse event reporting. Efficacy results in the oxybutynin chloride topical gel and placebo groups were compared by ANCOVA with last observations carried forward. RESULTS: A total of 789 randomized patients, including 704 women (89.2%), with a mean age of 59 years were assigned to treatment with oxybutynin chloride topical gel (389) or placebo (400). The mean number of urge incontinence episodes decreased significantly more in patients treated with oxybutynin chloride topical gel than in those given placebo (-3.0 vs -2.5 per day, p <0.0001). Mean urinary frequency decreased (-2.7 per day, p = 0.0017) and voided volume increased (21.0 ml, p = 0.0018) significantly more in the oxybutynin chloride group than in the placebo group (-2.0 per day and 3.8 ml, respectively). Treatment related dry mouth was more frequent in the oxybutynin chloride group than in the placebo group (27 of 389 patients or 6.9% vs 11 of 400 or 2.8%). Application site reactions were infrequently observed in the oxybutynin chloride and placebo groups (21 of 389 patients or 5.4% and 4 of 400 or 1.0%, respectively). No serious treatment related adverse events occurred. CONCLUSIONS: Oxybutynin chloride topical gel was efficacious in improving overactive bladder symptoms and was well tolerated in adult patients.
机译:目的:我们评估了奥昔布宁氯化物局部凝胶与安慰剂在膀胱过度活动症成人中的疗效和安全性。材料和方法:在美国76家诊所进行的随机,平行组,双盲,安慰剂对照研究OG05009入选了18岁或18岁以上患有急迫性尿失禁的男性和女性。合格的患者每天接受1克奥昔布宁氯化物局部用凝胶治疗(每重量10%重量的奥昔布宁乙醇基制剂)或匹配的安慰剂,每天一次,持续12周。使用3天尿日记的数据评估疗效,主要结果是急迫性尿失禁发作次数与基线相比发生了变化。通过不良事件报告监测安全性。通过ANCOVA比较了奥昔布宁氯化物局部凝胶和安慰剂组的疗效结果,并进行了最后的观察。结果:总共789例随机分组的患者,包括704名女性(89.2%),平均年龄为59岁,被分配接受氯化奥昔布宁局部用凝胶剂(389)或安慰剂(400)的治疗。用盐酸奥昔布宁局部用凝胶治疗的患者的急迫性尿失禁发作的平均减少幅度明显大于接受安慰剂的患者(-3.0 vs -2.5每天,p <0.0001)。盐酸奥昔布宁组的平均尿频下降(每天-2.7,p = 0.0017),排尿量增加(21.0 ml,p = 0.0018),比安慰剂组明显多(分别为-2.0每天和3.8 ml)。盐酸奥昔布宁组与安慰剂组相比,与治疗有关的口干更为频繁(389例患者中的27例,占6.9%,而400例患者中的11例,占2.8%)。在氯丁酸奥昔布宁和安慰剂组中很少观察到应用部位反应(分别为389例患者中的21例,分别为5.4%和400%或1.0%中的4个)。没有发生与治疗相关的严重不良事件。结论:奥昔布宁氯化物局部凝胶可有效改善膀胱过度活动症,在成年患者中耐受性良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号